Information Provided By: 
Fly News Breaks for January 29, 2016
JAZZ
Jan 29, 2016 | 06:55 EDT
Deutsche Bank analyst Gregg Gilbert says 2016 could be a pivotal year for Jazz Pharmaceuticals. The analyst sees several potential catalysts for the shares, including potentially greater certainty on Xyrem duration via a patent settlement or a win in court, FDA approval of defibrotide and acquisitions supported by the company's under-leveraged balance sheet. Gilbert keeps a Buy rating on Jazz with a $167 price target.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
